Champions Oncology (NASDAQ:CSBR) Share Price Passes Below Two Hundred Day Moving Average – Time to Sell?

Champions Oncology, Inc. (NASDAQ:CSBR) shares passed below its two hundred day moving average during trading on Thursday . The stock has a two hundred day moving average of $6.48 and traded as low as $5.85. Champions Oncology shares last traded at $6.04, with a volume of 5,373 shares trading hands.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings lowered Champions Oncology from a “hold (c-)” rating to a “sell (d-)” rating in a report on Monday, March 16th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company has an average rating of “Sell”.

Champions Oncology Stock Performance

The stock has a 50 day moving average of $5.97 and a two-hundred day moving average of $6.48. The stock has a market cap of $83.88 million, a PE ratio of -37.75 and a beta of 0.40.

Institutional Investors Weigh In On Champions Oncology

A number of institutional investors have recently bought and sold shares of CSBR. XTX Topco Ltd acquired a new stake in Champions Oncology during the 2nd quarter worth about $103,000. Essex Investment Management Co. LLC acquired a new stake in Champions Oncology during the 4th quarter worth about $126,000. Jane Street Group LLC acquired a new stake in Champions Oncology during the 1st quarter worth about $200,000. Goldman Sachs Group Inc. acquired a new stake in Champions Oncology during the 1st quarter worth about $201,000. Finally, Acadian Asset Management LLC boosted its position in Champions Oncology by 28.7% during the 1st quarter. Acadian Asset Management LLC now owns 39,511 shares of the biotechnology company’s stock worth $341,000 after acquiring an additional 8,814 shares during the period. 41.30% of the stock is currently owned by institutional investors and hedge funds.

About Champions Oncology

Champions Oncology, Inc engages in the development and sale of technology solutions and products to personalize the development and use of oncology drugs. Its technology platform, TumorGraft, is a novel approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. It uses its technology to offer solutions to Translational Oncology Solutions, which includes pharmaceutical and biotechnology companies; and Personalized Oncology, which assists physicians in developing personalized treatment options for their cancer patients.